This suggests that PPARγ should be considered a prospective target for GBM therapy, and the data simultaneously raise an important set of issues regarding which subsets of individuals or specific tumor subtypes are responsive to PPARγ agonizts and what still needs to be elucidated regarding the molecular understanding of receptor action. Here, PPARG is linked to glioblastoma.